论文部分内容阅读
生物医疗领域的产学合作在开发健康的创新治疗方法中起到重要作用,但是大多数的研究合作仍然发生在偶然的机会,生物医药领域目前广泛的重磅创新模式则面临成本过高的财务担忧。作为创新产学合作典范的学术医学中心(AMC)模式,能够打破现行做法,通过有效信息分类和非排他性竞争前合作,多方利益群体通过协同合作,能够更有效地识别和寻求创新差距、突破发现解决方案,并促进新临床研究。不可否认,产学合作关系同样面临利益、文化和资源的多重冲突和挑战。为了发挥产学合作互动在生物医药领域创新的巨大潜力,需要对产业和学术的创新活动进行更多的平衡,需要重视若干方面的组织管理,产学合作将会继续在开发新治疗方法中起到重要作用。
Industry-academia collaboration in biomedical research plays an important role in developing innovative treatments of health, but most research collaborations still happen by chance, and the current extensive heavyweight innovation paradigm in the biomedical sector faces the high cost of finance Worry. The AMC model, a model for innovation-university-industry cooperation, can break the current practice of effective information classification and non-exclusive pre-competition cooperation so that multi-stakeholder groups can identify and seek innovative gaps more effectively through breakthroughs in discovery Solutions and promote new clinical research. Admittedly, the cooperation between industries and industries also faces multiple conflicts and challenges of interests, cultures and resources. In order to bring into play the great potential of innovation in bio-medicine in the cooperation between industry and education, we need to strike more balance in the innovation activities of industry and scholarship. We need to attach importance to the management of certain aspects and the cooperation between industry and education will continue in the development of new treatments To the important role.